Immune checkpoint inhibition therapies, targeting cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) have ameliorated outcomes of several different cancer types including metastatic melanoma and others (12, 13). This evidence concerns the gene PDCD1 and cancer.